Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
TerrAscend Corp. filed its Q3 2026 report showing 308,921,051 common shares outstanding as of November 4, 2026. The filing highlights significant regulatory developments, including a rescheduling hearing for marijuana held in mid-2026 and the company's strategic exit from the Michigan market.
For the nine months ended September 30, 2026, Castellum, Inc. reported revenues of $42.9 million, a 6.3% increase year-over-year, though it recorded a net loss of $1.8 million. The company highlighted risks related to the lingering effects of the U.S. DOGE Service Temporary Organization on federal procurement processes and agency staffing.
Conduent Inc. reported a decline in revenue to $534 million for Q3 2026 compared to $605 million in the prior year period, with a net loss of $49 million. The company's financial position was impacted by restructuring costs and losses from discontinued operations, while total equity decreased to $471 million as of September 30, 2026.
Corsair Gaming reported Q3 2026 revenue of $367.0 million, up 6% year-over-year and exceeding its previous guidance range. The company saw strong performance in its Gaming Components and Systems segment, particularly in memory products, while narrowing its GAAP net loss to $2.4 million. Management raised the full-year 2026 outlook based on diversified portfolio growth and momentum heading into the holiday season.
News Corp held its 2026 Annual Meeting of Stockholders, where shareholders elected six directors, ratified Ernst & Young LLP as auditors, and approved executive compensation. During the meeting, leadership highlighted record fiscal 2026 results, including $9 billion in revenue and a significant acceleration of the company's stock buyback program to $643 million.
“Fiscal 2026 marked another record year for the company, a testament to our essential journalism, expert analysis and high-quality data and information, which are irreplaceable commodities in the AI age.”
Lachlan K. Murdoch, Chair
“To echo our Chair, fiscal 2026 was a record-breaking year for News Corp as we delivered record revenue and profitability on a continuing operations basis. Revenues rose 7% to $9 billion, Total Segment EBITDA increased 15% to over $1.6 billion and free cash flow increased significantly, rising 42% to $811 million.”
SoundHound AI reported record Q3 2026 revenue of $62.4 million, a 48.5% year-over-year increase, and provided guidance to reach adjusted EBITDA profitability by the second half of 2027. Alongside the results, the company announced a restructuring plan involving a 27% workforce reduction to align resources with strategic priorities following its acquisition of LivePerson.
Term
Q3 2026
“This is a milestone moment for SoundHound. We announced another record quarter, closed our acquisition of LivePerson, and guided that the company will be adjusted EBITDA profitable within the second half of 2027.”
Keyvan Mohajer, CEO and Co-Founder of SoundHound AI
“Since closing the LivePerson acquisition, we have moved swiftly and decisively to integrate the businesses and realize substantial cost and revenue synergies. At the same time, we are improving our quality of earnings by shifting upfront license deals to hosted structures and exiting non-core, dilutive business lines, making our revenue more stable and predictable.”
Wynn Resorts reported Q3 2026 operating revenues of $1.69 billion, a decrease from $1.83 billion in the prior year, primarily due to lower hold rates in Las Vegas and softer market conditions in Macau. The company also declared a quarterly cash dividend of $0.25 per share and noted significant construction progress on the Wynn Al Marjan Island project in the UAE.
Term
Q3 2026
“Our third quarter results demonstrated strong operational discipline from the teams in each of our regions. Wynn Las Vegas and our Macau properties both saw healthy demand amid slower market conditions. Wynn Las Vegas was also negatively impacted by a hold rate outside of our expected range.”
Lexicon Pharmaceuticals reported a net loss of $46.8 million for the nine months ended September 30, 2026, compared to $34.8 million in the prior year period. The company strengthened its balance sheet through common and preferred stock issuances, ending the period with $183.2 million in cash and short-term investments.
As of September 30, 2026, the Trust held $2.48 billion in net assets, representing 929,892 Ether, with approximately 80% of its holdings being staked. For the nine months ended September 30, 2026, the Trust generated $26.7 million in staking reward income but recorded a net decrease in net assets from operations of $197.1 million, primarily driven by $229.3 million in realized losses.
The Joint Corp. reported Q3 2026 revenue of $13.6 million and net income from continuing operations of $1.5 million. The Board of Directors also authorized an additional $5.0 million for its stock repurchase program, following $3.8 million in repurchases during the quarter.
“Our third quarter results reflect growth in our active membership cou”
Sanjiv Razdan, President and Chief Executive Officer
MP Materials reported Q3 2026 financial results, highlighted by a 176% year-over-year revenue increase to $147.7 million and a return to positive Adjusted EBITDA of $41.1 million. The company achieved a significant operational milestone by completing the GM magnet qualification process, with saleable deliveries and revenue expected to commence in Q4 2026.
Term
Q3 2026
“MP Materials delivered a strong quarter of growth across production, sales, and earnings. Most importantly, we completed the GM qualification process, with saleable magnet deliveries and revenue beginning in the fourth quarter. This milestone is the result of years of compounding capabilities across the MP platform and marks an inflection point for our business and mission.”
James Litinsky, Founder, Chairman and CEO of MP Materials
Nutex Health reported third quarter 2026 financial results, including net income of $40.2 million and total revenue of $217.6 million. While hospital division visits increased 18.1% year-over-year, total revenue decreased 18.7% primarily due to favorable revenue recognition adjustments that occurred in the prior year period.
ARS Pharmaceuticals reported Q3 2026 financial results with total revenue of $37.7 million, driven by $33.4 million in U.S. net product revenue for neffy. The company achieved a 5% overall U.S. market share for neffy and reaffirmed its path to cash flow breakeven by year-end 2027.
Term
Q3 2026
“In August, we committed to three corporate priorities – steady market share gains with neffy, greater financial discipline with a path to cash flow breakeven by year-end 2027, and expansion of our needle-free epinephrine platform beyond anaphylaxis. I’m proud to report that our team has delivered on each.”
Donn Casale, President and Chief Executive Officer
“neffy is a highly differentiated product in a large market with genuine demand, and I am confident it can become the standard of care in the epinephrine market.”
Sumisho Air Lease reported Q3 2026 net income of $93.4 million on total revenues of $592.6 million, an 18.3% decrease year-over-year. The revenue decline was primarily driven by a lower weighted average net book value of flight equipment following significant aircraft sales. The company ended the quarter with 473 owned aircraft and $29.9 billion in total assets.
Affirm Holdings reported its first fiscal quarter 2027 results, achieving its 8th consecutive quarter of GAAP profitability with net income of $83 million. The company saw significant growth across key metrics, including a 35% year-over-year increase in Gross Merchandise Volume (GMV) to $14.4 billion and a 34% increase in revenue to $1.3 billion.
LifeStance Health Group reported a significant improvement in financial performance for the third quarter of 2026, with total revenue increasing to $455.9 million compared to $363.8 million in the prior year. The company achieved a net income of $22.4 million for the quarter, a substantial increase from $1.1 million in the same period of 2025, driven by strong growth in income from operations.
STERIS plc reported total revenues of $1,588.6 million for the quarter ended September 30, 2026, an 8.8% increase compared to the prior year. Net income attributable to shareholders rose to $213.7 million, driven by growth in both product and service segments, while the company continued its share repurchase program with $215.9 million spent in the first six months of the fiscal year.
Carlyle Secured Lending, Inc. reported its financial results for the third quarter of 2026, highlighting stable net investment income and a consistent portfolio performance focused on senior secured loans. The company maintained its quarterly dividend and reported a steady net asset value per share despite broader market volatility.
Opus Genetics CEO George Magrath Sells $110K of Stock
George Magrath, CEO, sold 28,258 shares of Opus Genetics, Inc. at $3.90 a share, worth $110K in total on Nov 3, 2026. Shares held after the trade: 2,010,636 (-1.4%).
Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for hematological and musculoskeletal disorders. The filing highlights ongoing Phase 2 trials for rinvatercept (KER-065) and elritercept (KER-050), the latter of which is being developed in collaboration with Takeda and Hansoh.
Aldeyra Therapeutics reported a net loss of $3.8 million for the third quarter of 2026, a significant reduction from the $7.7 million loss in the same period of 2025, primarily driven by lower research and development expenses. The company's cash position decreased to $41.0 million as of September 30, 2026, following the full repayment of its $15.0 million long-term debt during the year.
Doximity reported fiscal 2027 second quarter revenue of $174.5 million, up 4% year-over-year, with a net income of $34.7 million. The company highlighted record engagement and heavy investment in AI, with over 190 health systems now purchasing its AI suite.
Term
Q2 2027
“We delivered another quarter of record engagement while investing heavily in AI and maintaining a 51% adjusted EBITDA margin. More than 190 health systems have now purchased our AI suite, and with UpToDate and DoseCheck, we’re extending our lead in distribution and trust.”
ServisFirst Bancshares, Inc. has updated its investor presentation to include financial information and data for the current quarter. The presentation highlights the company's organic growth story and reports total assets of approximately $18.3 billion as of November 2026.
Grayscale Dogecoin Trust ETF reported net assets of $13.6 million as of September 30, 2026, a significant increase from $3.9 million at year-end 2025, driven primarily by $12.5 million in net capital share transactions. Despite a net increase in assets, the Trust experienced a net decrease in net assets from operations of $2.78 million for the nine months ended September 30, 2026, largely due to unrealized depreciation of its DOGE holdings.
Maravai LifeSciences Holdings, Inc. reported its Q3 2026 financial results, noting significant revenue dependency on CleanCap® for vaccine programs and ongoing risks from organizational changes and workforce reductions. As of October 29, 2026, the company had 149,254,467 Class A and 110,684,080 Class B shares outstanding, while maintaining its status as an accelerated filer.
For the quarter ended September 30, 2026, Parker-Hannifin reported net sales of $5.99 billion, an 18% increase from the prior year, and net income of $884 million. The company's balance sheet showed significant growth in total assets to $41.9 billion, primarily driven by a $9.1 billion acquisition that substantially increased goodwill and intangible assets.
MannKind Corporation reported third quarter 2026 total revenues of $101.9 million, a 24% increase year-over-year, driven by the commercial launch of Furoscix ReadyFlow and strong pediatric uptake for Afrezza. The company also highlighted positive Phase 1b results for its nintedanib DPI program and a new licensing collaboration with Rose Pharma for an inhaled GLP-1.
“The third quarter marked an important transition for MannKind as we shifted from delivering on three major catalysts to executing against them. We are focused on scaling two commercial launches while supporting three programs in IPF. Furoscix ReadyFlow is off to an exceptionally strong start, and we believe Furoscix will generate more revenue in the fourth quarter than it did in the first half of 2026. ReadyFlow significantly expands the opportunity ahead and reinforces our conviction that Furoscix can be transformational for MannKind and the patients we serve.”
Michael Castagna, Chief Executive Officer of MannKind
Quantinuum reported third quarter 2026 revenue of $9.1 million, a 233% year-over-year increase, driven by expanded enterprise reach and the largest cloud agreement in company history. The company raised its full-year 2026 revenue guidance to a range of $32 million to $35 million while maintaining a strong cash position of $1.94 billion.
Term
Q3 2026
“In the third-quarter, we extended our technology leadership in the critical area of fault-tolerance, added to our customer base, and expanded our routes to market. This accelerated momentum is supporting our raised revenue outlook for 2026 and giving us more confidence than ever in the opportunity in front of us.”
Rajeeb Hazra, President and Chief Executive Officer of Quantinuum
SINTX Technologies reported record third quarter 2026 revenue of $2.2 million, a more than tenfold increase compared to the prior year. The company significantly reduced its net loss by 55% to $1.6 million while advancing the commercialization of its SiNAPTIC Foot & Ankle Osteotomy Wedge System.
Term
Q3 2026
“Our third-quarter results represent a meaningful milestone in the commercial transformation of SINTX Technologies. The substantial increase in quarterly revenue, combined with significant improvements in gross profit and operating performance, demonstrates the potential of our advanced manufacturing platform as we convert investments over the past several years into revenue-building commercial opportunities.”
Eric Olson, Chief Executive Officer of SINTX
“We believe our performance this quarter demonstrates measurable progress toward building a commercially focused advanced materials company. With improving operating performance, expanding commercial activities, and continued investment in our proprietary technologies, we believe SINTX is well positioned to pursue additional growth opportunities in 2027.”
Eton Pharmaceuticals announced preliminary results from a pilot study of ET-700 for Wilson disease, demonstrating significantly improved gastrointestinal tolerability compared to GALZIN. While ET-700 showed a lower rate of adverse events (8% vs 67% for GALZIN), its copper absorption inhibition was more modest (12% reduction vs 46% for GALZIN), leading the company to plan additional study arms in 2027 for faster-release formulations.
“The tolerability findings are exciting and reinforce our belief that a slower release zinc can improve tolerability, which is a notorious issue with zinc treatment. We are encouraged by the initial results, which showed a benefit over placebo, and our next objective is to improve ET-700’s effect on copper absorption.”
Sean Brynjelsen, Chief Executive Officer of Eton Pharmaceuticals